NCT05395741 2026-03-25
Regbone
Institute of Mother and Child, Warsaw, Poland
Phase 1/2 Active not recruiting
Clinical Trials
32 trialsNCT03793361 2026-03-18
EREMISS
Centre Oscar Lambret
Phase 2 Completed
NCT01900743 2026-03-13
REGO-SARC
Centre Oscar Lambret
Phase 2 Completed
NCT04055220 2026-02-17
REGOSTA
Centre Leon Berard
Phase NA Recruiting
NCT06820957 2026-02-17
Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
Children's Oncology Group
Phase 2/3 Active not recruiting
NCT07379047 2026-01-30
GISTAR-1
Ningbo Newbay Technology Development Co., Ltd
Phase 2/3 Not yet recruiting
NCT06087263 2026-01-20
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05830084 2026-01-06
REGO-INTER-EWI
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Active not recruiting
NCT04803877 2025-10-31
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
Sarcoma Alliance for Research through Collaboration
Phase 2 Active not recruiting
NCT02389244 2025-09-16
REGOBONE
UNICANCER
Phase 2 Active not recruiting
NCT05366816 2025-09-09
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
University of Miami
Phase 2 Recruiting
NCT06321055 2025-05-20
An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States
Bayer
Completed
NCT04625907 2024-05-23
FaR-RMS
University of Birmingham
Phase 1/2 Recruiting
NCT02085148 2024-04-22
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Bayer
Phase 1 Completed
NCT02048371 2023-11-07
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT02106858 2023-07-24
StivargaPMS
Bayer
Completed
NCT02365441 2023-07-07
ALT GIST
Australasian Gastro-Intestinal Trials Group
Phase 2 Unknown
NCT05582031 2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2 Withdrawn
NCT02638766 2023-03-27
REGISTRI
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Completed
NCT03475953 2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2 Unknown
NCT03465722 2022-10-06
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Blueprint Medicines Corporation
Phase 3 Completed
NCT02307500 2022-09-10
RESOUND
Istituto Clinico Humanitas
Phase 2 Completed
NCT02048722 2022-04-25
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Northwestern University
Phase 2 Completed
NCT01933958 2022-04-01
Regorafenib Post-marketing Surveillance in Japan
Bayer
Completed
NCT02164240 2021-06-14
SURE
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01271712 2021-01-29
GRID
Bayer
Phase 3 Completed
NCT01068769 2020-08-24
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02889328 2020-01-09
Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs
Asan Medical Center
Phase 2 Completed
NCT02606097 2019-03-21
Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
Chang Gung Memorial Hospital
Phase 2 Completed
NCT02800330 2018-08-02
REGORA
Erasmus Medical Center
Phase 4 Completed
NCT01689376 2016-08-16
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
Bayer
No longer available
NCT01646593 2014-12-15
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
Bayer
No longer available